Page Title
Clinical Trial Finder
Restore CFTR Function Completed with Results
Study of VX-445 Triple Combination in Teens and Adults With Cystic Fibrosis (CF) Who Have One Copy of F508del and One Copy of a Gating or Residual Function Mutation (Vertex VX18-445-104)
This study evaluated the safety and effectiveness of VX-445 (elexacaftor), tezacaftor, and ivacaftor in combination called TRIKAFTA®. This study was for people with CF 12 years and older with one copy of the F508del mutation and one copy of a gating or residual function mutation.
All participants had a 4-week run-in period of either ivacaftor (IVA) or tezacaftor/ivacaftor (TEZ/IVA). Following the run-in, participants were randomly assigned to receive elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) or keep taking their IVA or TEZ/IVA for 8 weeks.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
12 Years and Older -
Mutation(s):
One Copy F508del -
FEV1% Predicted:
40 to 90%
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Study participants must have one copy of the F508del mutation and one copy of a gating or residual function mutation. Click here to see a list of eligible mutations.
Study Results
-
What We Learned:
In a population with F508del plus either a gating or residual function mutation, treatment with the 3-drug combination of elexacaftor/tezacaftor/ivacaftor for 8 weeks resulted in higher ppFEV1 and more normal sweat chloride concentration when compared with an active control group receiving ivacaftor alone or tezacaftor/ivacaftor treatment. No significant safety concerns were identified in this study of the 3-drug modulator elexacaftor/tezacaftor/ivacaftor.
-
Primary Findings:
Effectiveness:
This study was completed in July 2020. The study enrolled 258 patients ages 12 years and older with F508del-gating or F508del-residual function genotypes. After 4 weeks run-in with ivacaftor or tezacaftor/ivacaftor, patients were randomized to continue this modulator treatment alone (active control group) or to receive elexacaftor/tezacaftor/ivacaftor for 8 weeks.
The primary outcome was change in percent predicted FEV1 over the 8-week period, comparing the active control modulator started during the run-in period with the 3-drug combination of elexacaftor/tezacaftor/ivacaftor. The 8-week change in ppFEV1 was significantly greater in those receiving triple combination modulator ppFEV1. The average difference was 3.5 percentage points.
A key secondary outcome was the change in sweat chloride concentration over the same 8-week treatment period. The change in sweat chloride concentration was significantly greater in the group receiving triple combination modulator compared with the active control groups. The average difference in sweat chloride change between the two groups was 23.1 mmol/L.
Safety:
The number of all adverse events and treatment-related adverse events were not significantly different between the groups.
-
Citation:
N Eng J Med 2021;DOI 0.1056/NEJMoa2100665;385:815-825
For current information about the overall development status of this drug, please check the Drug Development Pipeline.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
Yes -
Placebo Controlled: ?more info
No -
Length of Participation:
20 weeks -
Number of Study Visits:
8
Additional Information
-
Phase: ?more info
Phase Three -
Study Sponsor: ?more info
Vertex -
Study Drugs:
Eligibility
See other primary eligibility criteria for more information.
-
Age:
12 Years and Older -
Mutation(s):
One Copy F508del -
FEV1% Predicted:
40 to 90%
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Study participants must have one copy of the F508del mutation and one copy of a gating or residual function mutation. Click here to see a list of eligible mutations.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More